Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations

Robert W. Shafer, Michael J. Kozal, Mark A. Winters, Astrid K.N. Iversen, David A. Katzenstein, Margaret V. Ragni, William A. Meyer, Phalquni Gupta, Suraiya Rasheed, Robert Coombs, Michael Katzman, Susan Fiscus, Thomas C. Merigan

Research output: Contribution to journalArticle

190 Citations (Scopus)

Abstract

Drug resistance conferred by specific human immunodeficiency virus type 1 (HIV-1) pol gene mutations has been associated with clinical progression in HIV-infected patients receiving antiretroviral therapy. This study examined drug susceptibilities and pol mutations of HIV-1 strains from patients treated for 1 year with zidovudine, didanosine (ddl), or zidovudine and ddI. Ten (42%) of 24 patients receiving combination therapy versus 8/26 (31%) receiving only zidovudine had HIV-1 strains with phenotypic zidovudine resistance or a zidovudine resistance pol mutation at codon 215 (P =.6). In contrast, a ddI resistance mutation at codon 74 was less common among patients receiving combination therapy (2/24) than among those receiving ddI only (17/26; P <.001). Two patients receiving combination therapy developed resistance to zidovudine and ddI; they had HIV strains with amino acid mutations at codons 62, 75, 77, 116, and 151. Combination therapy with zidovudine and ddI selects for zidovudine-resistant HIV-1 strains lacking a ddI resistance mutation and for multidrug-resistant strains containing novel pol mutations.

Original languageEnglish (US)
Pages (from-to)722-729
Number of pages8
JournalJournal of Infectious Diseases
Volume169
Issue number4
DOIs
StatePublished - Jan 1 1994

Fingerprint

pol Genes
Didanosine
Zidovudine
HIV-1
Mutation
Pharmaceutical Preparations
Codon
Therapeutics
HIV
Multiple Drug Resistance
Drug Resistance
Amino Acids

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Shafer, Robert W. ; Kozal, Michael J. ; Winters, Mark A. ; Iversen, Astrid K.N. ; Katzenstein, David A. ; Ragni, Margaret V. ; Meyer, William A. ; Gupta, Phalquni ; Rasheed, Suraiya ; Coombs, Robert ; Katzman, Michael ; Fiscus, Susan ; Merigan, Thomas C. / Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. In: Journal of Infectious Diseases. 1994 ; Vol. 169, No. 4. pp. 722-729.
@article{dadfabb6542d4d72aac72e5509878d95,
title = "Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations",
abstract = "Drug resistance conferred by specific human immunodeficiency virus type 1 (HIV-1) pol gene mutations has been associated with clinical progression in HIV-infected patients receiving antiretroviral therapy. This study examined drug susceptibilities and pol mutations of HIV-1 strains from patients treated for 1 year with zidovudine, didanosine (ddl), or zidovudine and ddI. Ten (42{\%}) of 24 patients receiving combination therapy versus 8/26 (31{\%}) receiving only zidovudine had HIV-1 strains with phenotypic zidovudine resistance or a zidovudine resistance pol mutation at codon 215 (P =.6). In contrast, a ddI resistance mutation at codon 74 was less common among patients receiving combination therapy (2/24) than among those receiving ddI only (17/26; P <.001). Two patients receiving combination therapy developed resistance to zidovudine and ddI; they had HIV strains with amino acid mutations at codons 62, 75, 77, 116, and 151. Combination therapy with zidovudine and ddI selects for zidovudine-resistant HIV-1 strains lacking a ddI resistance mutation and for multidrug-resistant strains containing novel pol mutations.",
author = "Shafer, {Robert W.} and Kozal, {Michael J.} and Winters, {Mark A.} and Iversen, {Astrid K.N.} and Katzenstein, {David A.} and Ragni, {Margaret V.} and Meyer, {William A.} and Phalquni Gupta and Suraiya Rasheed and Robert Coombs and Michael Katzman and Susan Fiscus and Merigan, {Thomas C.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1093/infdis/169.4.722",
language = "English (US)",
volume = "169",
pages = "722--729",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

Shafer, RW, Kozal, MJ, Winters, MA, Iversen, AKN, Katzenstein, DA, Ragni, MV, Meyer, WA, Gupta, P, Rasheed, S, Coombs, R, Katzman, M, Fiscus, S & Merigan, TC 1994, 'Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations', Journal of Infectious Diseases, vol. 169, no. 4, pp. 722-729. https://doi.org/10.1093/infdis/169.4.722

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. / Shafer, Robert W.; Kozal, Michael J.; Winters, Mark A.; Iversen, Astrid K.N.; Katzenstein, David A.; Ragni, Margaret V.; Meyer, William A.; Gupta, Phalquni; Rasheed, Suraiya; Coombs, Robert; Katzman, Michael; Fiscus, Susan; Merigan, Thomas C.

In: Journal of Infectious Diseases, Vol. 169, No. 4, 01.01.1994, p. 722-729.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations

AU - Shafer, Robert W.

AU - Kozal, Michael J.

AU - Winters, Mark A.

AU - Iversen, Astrid K.N.

AU - Katzenstein, David A.

AU - Ragni, Margaret V.

AU - Meyer, William A.

AU - Gupta, Phalquni

AU - Rasheed, Suraiya

AU - Coombs, Robert

AU - Katzman, Michael

AU - Fiscus, Susan

AU - Merigan, Thomas C.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Drug resistance conferred by specific human immunodeficiency virus type 1 (HIV-1) pol gene mutations has been associated with clinical progression in HIV-infected patients receiving antiretroviral therapy. This study examined drug susceptibilities and pol mutations of HIV-1 strains from patients treated for 1 year with zidovudine, didanosine (ddl), or zidovudine and ddI. Ten (42%) of 24 patients receiving combination therapy versus 8/26 (31%) receiving only zidovudine had HIV-1 strains with phenotypic zidovudine resistance or a zidovudine resistance pol mutation at codon 215 (P =.6). In contrast, a ddI resistance mutation at codon 74 was less common among patients receiving combination therapy (2/24) than among those receiving ddI only (17/26; P <.001). Two patients receiving combination therapy developed resistance to zidovudine and ddI; they had HIV strains with amino acid mutations at codons 62, 75, 77, 116, and 151. Combination therapy with zidovudine and ddI selects for zidovudine-resistant HIV-1 strains lacking a ddI resistance mutation and for multidrug-resistant strains containing novel pol mutations.

AB - Drug resistance conferred by specific human immunodeficiency virus type 1 (HIV-1) pol gene mutations has been associated with clinical progression in HIV-infected patients receiving antiretroviral therapy. This study examined drug susceptibilities and pol mutations of HIV-1 strains from patients treated for 1 year with zidovudine, didanosine (ddl), or zidovudine and ddI. Ten (42%) of 24 patients receiving combination therapy versus 8/26 (31%) receiving only zidovudine had HIV-1 strains with phenotypic zidovudine resistance or a zidovudine resistance pol mutation at codon 215 (P =.6). In contrast, a ddI resistance mutation at codon 74 was less common among patients receiving combination therapy (2/24) than among those receiving ddI only (17/26; P <.001). Two patients receiving combination therapy developed resistance to zidovudine and ddI; they had HIV strains with amino acid mutations at codons 62, 75, 77, 116, and 151. Combination therapy with zidovudine and ddI selects for zidovudine-resistant HIV-1 strains lacking a ddI resistance mutation and for multidrug-resistant strains containing novel pol mutations.

UR - http://www.scopus.com/inward/record.url?scp=0028273314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028273314&partnerID=8YFLogxK

U2 - 10.1093/infdis/169.4.722

DO - 10.1093/infdis/169.4.722

M3 - Article

VL - 169

SP - 722

EP - 729

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -